224 related articles for article (PubMed ID: 18829514)
1. A phase I trial of pemetrexed plus gemcitabine given biweekly with B-vitamin support in solid tumor malignancies or advanced epithelial ovarian cancer.
Hensley ML; Larkin J; Fury M; Gerst S; Tai DF; Sabbatini P; Konner J; Orlando M; Goss TL; Aghajanian CA
Clin Cancer Res; 2008 Oct; 14(19):6310-6. PubMed ID: 18829514
[TBL] [Abstract][Full Text] [Related]
2. Phase I dose-escalating study of biweekly fixed-dose rate gemcitabine plus pemetrexed in patients with advanced solid tumors.
Yuan Y; Cohen DJ; Love E; Yaw M; Levinson B; Nicol SJ; Hochster HS
Cancer Chemother Pharmacol; 2011 Aug; 68(2):371-8. PubMed ID: 20978761
[TBL] [Abstract][Full Text] [Related]
3. A dose escalation study of gemcitabine plus pemetrexed administered biweekly in patients with solid tumors.
Kalykaki A; Vamvakas L; Agelaki S; Kalbakis K; Vardakis N; Sfakiotaki G; Ignatiadis M; Saridaki Z; Karampeazis A; Mavroudis D; Georgoulias V
Oncology; 2006; 71(3-4):197-203. PubMed ID: 17641541
[TBL] [Abstract][Full Text] [Related]
4. Phase I study of a 3-drug regimen of gemcitabine/cisplatin/pemetrexed in patients with metastatic transitional cell carcinoma of the urothelium.
Hutson TE; Vukelja S; Atienza D; Awasthi S; Delaune R; Deutsch M; Dien PY; Gregory TF; Kolodziej MJ; Muscato JJ; Raju RN; Ruxer RL; Mull S; Ilegbodu D; Hood K; Nicol S; Berry W
Invest New Drugs; 2008 Apr; 26(2):151-8. PubMed ID: 18236006
[TBL] [Abstract][Full Text] [Related]
5. Phase I study of pemetrexed and pegylated liposomal doxorubicin in patients with refractory breast, ovarian, primary peritoneal, or fallopian tube cancer.
Richards DA; Loesch D; Vukelja SJ; Wu H; Hyman WJ; Nieves J; Wang Y; Hu S; Shonukan OO; Tai DF
Invest New Drugs; 2011 Oct; 29(5):963-70. PubMed ID: 20352294
[TBL] [Abstract][Full Text] [Related]
6. A phase 2 study of pemetrexed plus gemcitabine every 2 weeks for patients with recurrent or metastatic head and neck squamous cell cancer.
Fury MG; Haque S; Stambuk H; Shen R; Carlson D; Pfister D
Cancer; 2011 Feb; 117(4):795-801. PubMed ID: 20922785
[TBL] [Abstract][Full Text] [Related]
7. Phase I and pharmacokinetic study of the multitargeted antifolate pemetrexed in combination with oxaliplatin in patients with advanced solid tumors.
Misset JL; Gamelin E; Campone M; Delaloge S; Latz JE; Bozec L; Fumoleau P
Ann Oncol; 2004 Jul; 15(7):1123-9. PubMed ID: 15205208
[TBL] [Abstract][Full Text] [Related]
8. Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies.
Mani S; Vogelzang NJ; Bertucci D; Stadler WM; Schilsky RL; Ratain MJ
Cancer; 2001 Sep; 92(6):1567-76. PubMed ID: 11745236
[TBL] [Abstract][Full Text] [Related]
9. Phase I and pharmacokinetic study of pemetrexed with high-dose folic acid supplementation or multivitamin supplementation in patients with locally advanced or metastatic cancer.
Takimoto CH; Hammond-Thelin LA; Latz JE; Forero L; Beeram M; Forouzesh B; de Bono J; Tolcher AW; Patnaik A; Monroe P; Wood L; Schneck KB; Clark R; Rowinsky EK
Clin Cancer Res; 2007 May; 13(9):2675-83. PubMed ID: 17473199
[TBL] [Abstract][Full Text] [Related]
10. A phase II trial of pemetrexed and gemcitabine in patients with metastatic breast cancer who have received prior taxane therapy.
Pippen J; Elias AD; Neubauer M; Stokoe C; Vaughn LG; Wang Y; Orlando M; Shonukan O; Muscato J; O'Shaughnessy JA; Gralow J
Clin Breast Cancer; 2010 Apr; 10(2):148-53. PubMed ID: 20299319
[TBL] [Abstract][Full Text] [Related]
11. Pemetrexed and gemcitabine for biliary tract and gallbladder carcinomas: a North Central Cancer Treatment Group (NCCTG) phase I and II Trial, N9943.
Alberts SR; Sande JR; Foster NR; Quevedo FJ; McWilliams RR; Kugler JW; Fitch TR; Jaslowski AJ
J Gastrointest Cancer; 2007; 38(2-4):87-94. PubMed ID: 19023677
[TBL] [Abstract][Full Text] [Related]
12. Phase I dose escalation study of gemcitabine and paclitaxel plus colony-stimulating factors in previously treated patients with advanced breast and ovarian cancer.
Iaffaioli RV; Tortoriello A; Santangelo M; Turitto G; Libutti M; Benassai G; Frattolillo A; Ciccarelli PD; De Rosa P; Crovella F; Carbone I; Barbarisi A
Clin Oncol (R Coll Radiol); 2000; 12(4):251-5. PubMed ID: 11005695
[TBL] [Abstract][Full Text] [Related]
13. Phase I trial of vinflunine and pemetrexed in refractory solid tumors.
Sanoff HK; Davies J; Walko C; Buie L; Chiu WK; Ivanova A; O'Neil B; Stinchcombe TE; Keller K; Dees EC
Invest New Drugs; 2011 Feb; 29(1):131-6. PubMed ID: 19830387
[TBL] [Abstract][Full Text] [Related]
14. Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a phase II trial.
Simon GR; Verschraegen CF; Jänne PA; Langer CJ; Dowlati A; Gadgeel SM; Kelly K; Kalemkerian GP; Traynor AM; Peng G; Gill J; Obasaju CK; Kindler HL
J Clin Oncol; 2008 Jul; 26(21):3567-72. PubMed ID: 18640937
[TBL] [Abstract][Full Text] [Related]
15. Administration of pemetrexed immediately following gemcitabine as front-line therapy in advanced non-small cell lung cancer: a phase II trial.
Treat J; Bonomi P; McCleod M; Christiansen NP; Mintzer DM; Monberg MJ; Ye Z; Chen R; Obasaju CK
Lung Cancer; 2006 Jul; 53(1):77-83. PubMed ID: 16730854
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of biweekly pemetrexed and gemcitabine in patients with previously untreated advanced non-small cell lung cancer.
Spigel DR; Hainsworth JD; Barton JH; Patton JF; Zubkus JD; Simons L; Griner P; Burris HA; Greco FA
J Thorac Oncol; 2010 Jun; 5(6):841-5. PubMed ID: 20421819
[TBL] [Abstract][Full Text] [Related]
17. Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies.
Gray HJ; Bell-McGuinn K; Fleming GF; Cristea M; Xiong H; Sullivan D; Luo Y; McKee MD; Munasinghe W; Martin LP
Gynecol Oncol; 2018 Mar; 148(3):507-514. PubMed ID: 29352572
[TBL] [Abstract][Full Text] [Related]
18. A phase IB study of the pharmacokinetics of gemcitabine and pemetrexed, when administered in rapid sequence to patients with advanced solid tumors.
Dy GK; Suri A; Reid JM; Sloan JA; Pitot HC; Alberts SR; Goldberg RM; Atherton PJ; Hanson LJ; Burch PA; Rubin J; Erlichman C; Adjei AA
Cancer Chemother Pharmacol; 2005 Jun; 55(6):522-30. PubMed ID: 15754203
[TBL] [Abstract][Full Text] [Related]
19. Dose-escalation study of fixed-dose rate gemcitabine combined with capecitabine in advanced solid malignancies.
Attia S; Morgan-Meadows S; Holen KD; Bailey HH; Eickhoff JC; Schelman WR; Traynor AM; Mulkerin DL; Campbell TC; McFarland TA; Huie MS; Cleary JF; Tevaarwerk AJ; Alberti DB; Wilding G; Liu G
Cancer Chemother Pharmacol; 2009 Jun; 64(1):45-51. PubMed ID: 18841362
[TBL] [Abstract][Full Text] [Related]
20. A phase I dose-escalation and pharmacokinetic study of sunitinib in combination with pemetrexed in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer.
Chow LQ; Blais N; Jonker DJ; Laurie SA; Diab SG; Canil C; McWilliam M; Thall A; Ruiz-Garcia A; Zhang K; Tye L; Chao RC; Camidge DR
Cancer Chemother Pharmacol; 2012 Mar; 69(3):709-22. PubMed ID: 21989766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
